Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the year-ago period. This growth was primarily fueled by approximately $11 million in net sales of TONMYA, its recently approved treatment for fibromyalgia. The company's flagship medicine recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%. TONMYA now has coverage representing roughly 136 million lives across commercial, managed Medicare, and Medicaid channels, with expectations to reach 145 million when a managed Medicare agreement takes effect on Jan. 1, 2027.
The strong commercial performance of TONMYA underscores the market's reception of the first new fibromyalgia treatment in over 15 years. With its fully integrated commercial infrastructure, Tonix is well-positioned to capitalize on this momentum. Moreover, the company continues to advance its clinical pipeline, recently enrolling the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. According to the company, these resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial stability provides a runway to achieve key milestones, including the potential advancement of its pipeline candidates.
The implications of this announcement are significant for Tonix and its stakeholders. The robust sales of TONMYA not only validate the commercial potential of the product but also provide a revenue base to support ongoing research and development. The expansion of insurance coverage to more than 136 million lives enhances patient access, which could drive further prescription growth. Furthermore, the progress in the clinical pipeline, particularly the Phase 2 studies for major depressive disorder and Lyme disease prevention, highlights Tonix's commitment to addressing high unmet medical needs in CNS and immunology.
Tonix's achievements are noteworthy in the biotech sector, where commercial success often hinges on the ability to navigate regulatory and market challenges. The company's focus on CNS and immunology, areas with substantial patient populations and limited treatment options, positions it for potential long-term growth. As TONMYA continues to gain traction, and with a promising pipeline, Tonix is poised to make a meaningful impact on patient care.
For more information, visit the company's newsroom at https://nnw.fm/TNXP.
